Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

NCT03680417 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT03680417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03680417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
Lead sponsor
PT Bio Farma
Phase
Phase 4
Overall status
Completed
Start date
November 16, 2017
Completion date
August 1, 2018
Enrollment
590 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunogenicity, safety issues